The liver’s ability to regenerate after injury is among the most remarkable feats of human biology. Yet, chronic injuries such as those caused by alcohol abuse, metabolic syndromes, and drug-induced toxicity trigger maladaptive repair mechanisms. Hepatic stellate cells, typically quiescent and vitamin A-rich in a healthy environment, become activated upon injury, transforming into myofibroblast-like cells that secrete extracellular matrix (ECM) components excessively. The resulting fibrotic scar tissue stiffens the liver, disrupting its intricate architecture and culminating in irreversible cirrhosis. Although liver transplantation remains the definitive treatment at late disease stages, it is plagued by donor shortages and complex complications, underscoring the urgent need for alternative therapeutic strategies.

Addressing this critical gap, the team at Science Tokyo devised an organoid system, termed iPSC-derived hepatocyte–stellate cell surrounding organoid (iHSO), which recapitulates native liver microenvironments more accurately than previous in vitro models. By differentiating human iPSCs into hepatocyte-like cells (iPS-Heps) and hepatic stellate-like cells (iPS-HSCs), then co-culturing them to form spheroids where stellate cells envelop hepatocytes, the system mimics the liver’s architectural and functional anatomy. This configuration allows direct observation of cellular signaling pathways governing repair and fibrogenesis, a feat impossible in monotypic cultures or animal surrogates.

A pivotal revelation from this model is the dualistic communication between stellate cells and hepatocytes mediated by the adhesion molecule ICAM-1 and cytokine interleukin-1β (IL-1β). The iHSO demonstrated that quiescent iPS-HSCs sustain a cytokine-rich environment that promotes hepatocyte proliferation via the ICAM-1–IL-1β axis, highlighting a supportive stellate cell phenotype in liver regeneration. This intricate signaling relationship elucidates how HSCs can act both as protectors during tissue repair and as drivers of fibrosis when dysregulated, providing critical insights into temporal therapeutic targeting.

Moreover, the iHSO exhibited robust responses to hepatotoxic insult, exemplified by exposure to acetaminophen, a common analgesic known to induce liver injury at high doses. The organoids mirrored pathophysiological injuries seen in vivo, including hepatocyte damage and subsequent stellate cell activation. This injury modeling capacity validates the iHSO as a valuable experimental platform for investigating drug-induced liver injury mechanisms and screening potential hepatoprotective agents, bridging a vital translational gap.

Chronic liver disease constitutes a burgeoning global health crisis, with over four million adults afflicted in the United States alone, and rising incidence rates documented in countries like Japan due to lifestyle and metabolic factors. Despite increased awareness, therapeutic options capable of halting or reversing fibrosis before catastrophic liver failure remain elusive. The human-based iHSO organoid presents a paradigm shift by offering a scalable, physiologically relevant tool for dissecting fibrosis evolution and for accelerating the discovery of anti-fibrotic drugs with greater predictive validity than existing animal models.

Beyond pathological applications, the organoid system opens new avenues in regenerative medicine. Understanding stellate cell heterogeneity — from quiescence to activation states — and their influence on hepatocyte survival and proliferation sets the stage for engineering next-generation bioartificial livers. Such constructs could one day supplement or replace conventional transplants, mitigating immunological rejection risks and donor scarcity.

The research team, led by Professors Sei Kakinuma and Yasuhiro Asahina alongside Assistant Professor Masato Miyoshi and graduate student Tomohiro Mochida, showcases how sophisticated in vitro models can powerfully simulate in vivo biology. Their findings, published in September 2025’s issue of Stem Cell Reports, underscore the transformative potential of organoid platforms in resolving complex cell-to-cell communication pathways essential to liver homeostasis and pathology.

This study not only validates the iHSO as a human-relevant model for liver fibrosis research but also spotlights ICAM-1 and IL-1β as promising molecular targets. Future therapeutic strategies might exploit these pathways to modulate stellate cell behavior, fine-tuning the balance between repair and fibrosis. Such interventions could forestall progression to cirrhosis, reducing the global burden of liver disease and diminishing the reliance on transplantation.

The Institute of Science Tokyo, born from the union of Tokyo Medical and Dental University and Tokyo Institute of Technology, reflects a forward-looking mission to harness fundamental and translational science in advancing human health. With the iHSO model, they have laid a solid foundation for future exploration of hepatic diseases, offering hope that one day, chronic liver injuries will be manageable and even reversible.

In sum, this pioneering organoid system provides a vital, human-based window into the cellular dynamics underlying chronic liver diseases. It redefines experimental possibilities in fibrosis research, opening pathways to innovative drug development and regenerative therapies. As the global community grapples with the rising incidence of liver pathologies, such scientific innovations stand to chart a new course toward addressing one of medicine’s most daunting challenges.

Subject of Research: Cells

Article Title: Crosstalk via ICAM-1 enhances supportive phenotype of stellate cells and drives hepatocyte proliferation in iPSC-derived hepatic organoids

News Publication Date: 18-Sep-2025

Web References:
https://www.cell.com/stem-cell-reports/fulltext/S2213-6711(25)00246-2?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2213671125002462%3Fshowall%3Dtrue

References:
Kakinuma S, Asahina Y, Miyoshi M, Mochida T, et al. Crosstalk via ICAM-1 enhances supportive phenotype of stellate cells and drives hepatocyte proliferation in iPSC-derived hepatic organoids. Stem Cell Reports. 2025 Sep 18. DOI: 10.1016/j.stemcr.2025.102642

Image Credits: Institute of Science Tokyo

Keywords: Liver damage, Diseases and disorders, Medical treatments, Clinical medicine, Health and medicine

Pancreatic cancer remains one of the most aggressive malignancies, characterized by late diagnosis and poor prognosis. It is crucial to understand the cellular interactions that facilitate its progression. The study under review illustrates how pancreatic cancer cells communicate with liver cells via extracellular vesicles. These vesicles serve as vehicles for the transfer of bioactive molecules, including microRNAs, which can modulate various cellular functions. This research highlights the significant role that EVs play in establishing a pro-tumorigenic environment in distant organs, particularly the liver.

The exploration of microRNA-25-3p is particularly noteworthy. This small, non-coding RNA has been implicated in various cellular processes, including proliferation, survival, and differentiation. In the context of pancreatic cancer, microRNA-25-3p appears to facilitate the activation of hepatic stellate cells, which are crucial players in liver fibrosis and cancer progression. The activation of HSCs leads to the production of fibrogenic factors, which further enhances the tumor microenvironment conducive to metastasis. Understanding this relationship could unearth potential diagnostic and therapeutic targets.

The methodology employed in this study is robust and thorough. Researchers utilized a combination of in vitro and in vivo models to elucidate the role of microRNA-25-3p in HSC activation. This dual approach ensures that findings are not only relevant in a controlled laboratory environment but also hold true in biological systems. By isolating EVs from pancreatic cancer cell cultures, the study successfully demonstrates that these vesicles are enriched in microRNA-25-3p, establishing a direct link between the cancer cells and HSCs.

Further analysis revealed that treatment of HSCs with EVs containing microRNA-25-3p resulted in enhanced activation markers. This was evidenced by increased expression of α-smooth muscle actin (α-SMA) and collagen production, both of which are indicators of stellate cell activation. The study meticulously quantified these changes, reinforcing the assertion that microRNA-25-3p plays a pivotal role in modulating the behavior of HSCs in response to pancreatic tumor-derived signals.

Equally important is the exploration of the signaling pathways involved in this interaction. The findings suggest that microRNA-25-3p mediates its effects by targeting specific genes responsible for regulating HSC activation. Such insights into the molecular mechanisms at play provide a comprehensive understanding of how pancreatic cancer cells manipulate their environment to favor disease progression. This knowledge could inform the development of novel interventions aimed at disrupting these signaling pathways, potentially arresting cancer spread.

The study’s results have far-reaching implications for the management of pancreatic cancer. Given the limited treatment options available for this aggressive disease, identifying novel biomarkers and therapeutic targets is of utmost importance. MicroRNA-25-3p may serve as a valuable biomarker for early detection or for assessing the aggressiveness of pancreatic tumors. Moreover, targeting EV-associated microRNAs could represent a novel therapeutic strategy that disrupts the communication network between primary tumors and distant tissues.

As the field of cancer research continues to evolve, the focus on the tumor microenvironment and its interactions with systemic host responses is growing. This study contributes significantly to the understanding of how pancreatic cancer orchestrates its environment to thrive and spread. By elucidating the role of microRNAs in this process, researchers open the door to innovative approaches that may improve patient outcomes and survival rates.

Furthermore, the implications of these findings extend to other types of cancers as well. The principles of EV-mediated communication and microRNA-driven modulation of stromal cell activities could be applicable to a diverse array of malignancies. As more studies emerge in this field, it is likely that the understanding of EVs and microRNAs will lead to a paradigm shift in cancer biology, influencing both basic research and clinical practice.

In conclusion, the study of extracellular vesicle-associated microRNA-25-3p marking a significant advancement in the understanding of pancreatic cancer. It not only elucidates the mechanisms by which pancreatic cancer cells engage with hepatic stellate cells but also paves the way for future therapeutic strategies targeting these interactions. With ongoing research, there is a hope that these findings may eventually lead to improved prevention, diagnosis, and treatment modalities for this devastating disease.

This pioneering work is a reminder of the complexity of cancer biology and the importance of continued research in this area. It underscores the need for collaborative efforts across disciplines to unravel the complexities of cancer, aiming for a future where more effective therapies can be developed, ultimately saving lives in the fight against pancreatic cancer.

Explorations into the world of extracellular vesicles and their contents, such as microRNAs, represent a promising frontier in cancer research. As investigations deepen and technology advances, we may soon witness a shift in how we approach cancer therapy, transitioning from a one-size-fits-all mentality to more personalized, targeted strategies based on the molecular signatures of individual tumors. This study serves as a compelling example of how understanding the molecular interplay between tumor cells and their microenvironment can inform new therapeutic opportunities and address critical gaps in current cancer treatments.

Ultimately, this groundbreaking research illustrates that even the smallest molecules can play monumental roles in cancer progression. The potential for microRNA-25-3p and other similar biomolecules to impact treatment paradigms opens exciting avenues for further exploration and innovation in oncology, providing hope for better prospects in managing pancreatic and possibly other cancers in the future.

Subject of Research: Extracellular vesicle-associated microRNA-25-3p in pancreatic cancer progression
Article Title: Extracellular Vesicle-Associated MicroRNA-25-3p Derived from Pancreatic Cancer Cells Promotes Hepatic Stellate Cell Activation and Enhances Cancer Progression
Article References:

Wu, X., Shen, R., Yang, Z. et al. Extracellular Vesicle-Associated MicroRNA-25-3p Derived from Pancreatic Cancer Cells Promotes Hepatic Stellate Cell Activation and Enhances Cancer Progression. Biochem Genet (2025). https://doi.org/10.1007/s10528-025-11186-0

Image Credits: AI Generated
DOI: 10.1007/s10528-025-11186-0
Keywords: MicroRNA-25-3p, extracellular vesicles, pancreatic cancer, hepatic stellate cells, cancer progression